Advanced Practice Providers

Oncology nurses can educate patients about the potential indications for oncolytic virus therapy and connect them to available clinical trial opportunities.

Oncology Nursing News presents its top 5 articles covering the many advances made in cancer this year.

Pharmacologic strategies may be able to prevent abnormal uterine bleeding in patients undergoing stem cell transplant.

The role of circulating tumor DNA is growing: From detecting early disease to guiding treatment plans, clinicians are finding ctDNA testing increasingly important.

Nurses play an important role in the administration of biosimilars and the education of patients receiving them.

A nurse practitioner discusses the importance of compassionate end-of-life care discussions.

An oncology research nurse balances patient care with rigorous data collection, emphasizing communication and collaboration to advance cancer research.

Developing a strong working relationships and understanding the physical and emotional demands of the oncology specialty are some ways nurses can address burnout, an expert said.

Oncology nurses play a critical role in identifying and managing rare audiovestibular complications associated with immune checkpoint inhibitors to prevent permanent hearing loss and improve patients' quality of life.

Oncology rapid-access clinics should be essential to patient care standards across the oncology continuum.

A tiered level preceptor recognition program offers a cost-effective organizational intervention designed to acknowledge and incentivize the contributions of advanced practice preceptors.

Difficult conversations in cancer pain management should include core values and principles, setting realistic expectations, and building the patient-client relationship from the very beginning.

Veno-occlusive disease or sinusoidal obstruction syndrome is commonly associated as a complication with transplant in pediatric patients but can also be seen with chemotherapy alone.

Tia Wheatley, DNP, RN, AOCNS, BMTCN, and Shivani Gopalsami, RN, MSN, ANP-BC, AOCNP, discuss the benefits and challenges of multidisciplinary collaboration in hematopoietic stem cell transplant care.

A subgroup analysis showed that patients with hormone receptor–positive, HER2-negative advanced breast cancer who had de novo metastatic disease or late recurrence from neoadjuvant therapy achieved better outcomes with ribociclib plus letrozole.

Treatment with encorafenib in combination with cetuximab and binimetinib was active with a manageable safety profile in the first-line setting for patients with BRAF V600E–mutated metastatic colorectal cancer.

Brenda Martone MSN, ANP-BC, AOCNP, discusses what nurses need to know about safely treating patients with darolutamide.

Extending anastrozole treatment to 10 years in postmenopausal women with hormone receptor–positive breast cancer who have no evidence of disease after 5 years of standard-of-care treatments.

Enzalutamide plus leuprolide lowered the risk of metastases or death by 58% compared with placebo plus leuprolide.

Data presented during the ONS Annual Congress offers guidance for nurses caring for patients receiving darolutamide, docetaxel, and androgen deprivation therapy.

Managing ocular-related adverse effects with mirvetuximab soravtansine is key to helping patients with ovarian cancer stay on treatment.

An analysis of the cilta-cel safety profile yielded promising results, according to nurse investigators.

Milademetan, a MDM2 inhibitor, is associated with thrombocytopenia. An intermittent dosing schedule may help mitigate that adverse event.

Beth Faiman, PhD, MSN, APRN-BC, AOCN, discusses the growing need for advanced practitioner provider education and her role with the NP/PA center of excellence.

Patients who received pembrolizumab plus cisplatin and gemcitabine achieved a median overall survival of 12.7 months, compared with 10.9 months with cisplatin and gemcitabine alone.

Sarah Yenser Wood, RN, MSN, ANP, AOCNP, leads a nursing panel on adverse event management in renal cell carcinoma.

The pathologic complete response rate with durvalumab was 17.2% vs 4.3% with placebo, reflecting an absolute difference of 12.9%.

Early coordination with multiple specialty teams can maximize outcomes and improve quality of life for patients with complex metastatic disease.